Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|September 2, 2014
Lean Body Mass as a Clinical Outcome in Multicentric Castleman’s Disease
Author(s)Michael Sawyer, MD
Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.
Advertisement
Clinical Pearls
Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.
- Lean body mass is an important clinical outcome because it appears to be related to frailty in other literatures.
- The hope is to eventually study the relationship between fatigue, function, and lean body mass in patients on siltuximab.
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5